

Roland E Schmieder

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8309246/roland-e-schmieder-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

338 papers	33,507 citations	71 h-index	180 g-index
369 ext. papers	40,079 ext. citations	6.1 avg, IF	6.68 L-index

#	Paper	IF	Citations
338	Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 12	8.7	0
337	Response to: "Response to "Diagnosis and Treatment of Arterial Hypertension 2021".. <i>Kidney International</i> , 2022 ,	9.9	
336	Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 4	8.7	2
335	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium.. <i>Circulation</i> , 2022 , 145, 847-863	16.7	3
334	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.. <i>Lancet, The</i> , 2022 , 399, 1401-1410	40	11
333	Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial.. <i>Hypertension</i> , 2022 , 101161HYPERTENSIONAHA12118641	8.5	1
332	3D-Visualization of Neurovascular Compression at the Ventrolateral Medulla in Patients with Arterial Hypertension. <i>Clinical Neuroradiology</i> , 2021 , 31, 335-345	2.7	4
331	Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. <i>Cardiovascular Diabetology</i> , 2021 , 20, 219	8.7	6
330	Diagnosis and treatment of arterial hypertension 2021. <i>Kidney International</i> , 2021 ,	9.9	5
329	Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. <i>Journal of Hypertension</i> , 2021 , 39, 162-168	1.9	8
328	Neurogenic substance P-influences on action potential production in afferent neurons of the kidney?. <i>Pflugers Archiv European Journal of Physiology</i> , 2021 , 473, 633-646	4.6	1
327	Hypertrophic remodelling of retinal arterioles in patients with congestive heart failure. <i>ESC Heart Failure</i> , 2021 , 8, 1892-1900	3.7	1
326	Dependency of flow-mediated vasodilatation from basal nitric oxide activity. <i>Clinical Physiology and Functional Imaging</i> , 2021 , 41, 310-316	2.4	3
325	Response to: Cavagna et al The importance of considering cultural and environmental elements in an interventional model of care to fight hypertension in Africa. <i>Journal of Clinical Hypertension</i> , 2021 , 23, 1271-1272	2.3	1
324	Association of Noise Annoyance with Measured Renal Hemodynamic Changes. <i>Kidney and Blood Pressure Research</i> , 2021 , 46, 323-330	3.1	1
323	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	10
322	Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. <i>Journal of Human Hypertension</i> , 2021 ,	2.6	3

321	Renal denervation in patients with versus without chronic kidney disease: results from the global SYMPLICITY Registry with follow-up data of 3 years. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	6
320	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2909-2919	15.1	21
319	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. <i>Lancet, The</i> , 2021 , 397, 2476-2486	4.0	47
318	European Society of Hypertension position paper on renal denervation 2021. <i>Journal of Hypertension</i> , 2021 , 39, 1733-1741	1.9	21
317	Kriterien der Deutschen Gesellschaft für Kardiologie Herz- und Kreislaufforschung e. V. (DGK), der Deutschen Hochdruckliga e. V. DHL / Deutschen Gesellschaft für Hypertonie und Prävention und der Deutschen Gesellschaft für Nephrologie (DGfN) zur Zertifizierung von Renale-Denervations-Zentren (RDZ) Update. <i>Kardiologie</i> , 2021 , 15, 463-470	0.6	0
316	Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. <i>Clinical Research in Cardiology</i> , 2021 , 110, 725-731	6.1	7
315	How to measure retinal microperfusion in patients with arterial hypertension. <i>Blood Pressure</i> , 2021 , 30, 4-19	1.7	3
314	Reference values of retinal microcirculation parameters derived from a population random sample. <i>Microvascular Research</i> , 2021 , 134, 104117	3.7	3
313	Novel approaches to management of hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2021 , 30, 54-62	3.5	2
312	Improved blood pressure control via a novel chronic disease management model of care in sub-Saharan Africa: Real-world program implementation results. <i>Journal of Clinical Hypertension</i> , 2021 , 23, 785-792	2.3	4
311	Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. <i>Journal of Hypertension</i> , 2021 , 39, 1602-1610	1.9	0
310	Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction. <i>ESC Heart Failure</i> , 2021 , 8, 1562-1570	3.7	1
309	Identifying Isolated Systolic Hypertension From Upper-Arm Cuff Blood Pressure Compared With Invasive Measurements. <i>Hypertension</i> , 2021 , 77, 632-639	8.5	1
308	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. <i>Journal of Hypertension</i> , 2021 , 39, 766-774	1.9	2
307	Neurovascular Compression in Arterial Hypertension: Correlation of Clinical Data to 3D-Visualizations of MRI-Findings. <i>Open Neuroimaging Journal</i> , 2021 , 14, 16-27	0.1	
306	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1028-1038	15.1	5
305	Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. <i>American Heart Journal</i> , 2021 , 239, 90-99	4.9	4
304	Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. <i>ESC Heart Failure</i> , 2021 ,	3.7	2

303	Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. <i>Cardiovascular Diabetology</i> , 2021 , 20, 178	8.7	2
302	Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2021 , 14, e010075	6	3
301	Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 108055	3.2	0
300	Detection of Changes in Renal Blood Flow Using Arterial Spin Labeling MRI. <i>American Journal of Nephrology</i> , 2021 , 52, 69-75	4.6	
299	Copeptin Levels in Patients With Treatment-Resistant Hypertension Before and 6 Months After Renal Denervation. <i>American Journal of Hypertension</i> , 2020 , 33, 182-189	2.3	1
298	12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 2922-2933	5	19
297	Renal Denervation in High-Risk Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2879-2888	15.1	41
296	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. <i>Lancet, The</i> , 2020 , 395, 1444-1451	40	166
295	Changes in Stroke Volume After Renal Denervation: Insight From Cardiac Magnetic Resonance Imaging. <i>Hypertension</i> , 2020 , 75, 707-713	8.5	8
294	Aortic stiffness is not only associated with structural but also functional parameters of retinal microcirculation. <i>Microvascular Research</i> , 2020 , 129, 103974	3.7	7
293	Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 471-484	5	30
292	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. <i>Clinical Research in Cardiology</i> , 2020 , 109, 200-202	6.1	15
291	Influence of Age on Upper Arm Cuff Blood Pressure Measurement. <i>Hypertension</i> , 2020 , 75, 844-850	8.5	15
290	Facing the Challenge of Lowering Blood Pressure and Cholesterol in the Same Patient: Report of a Symposium at the European Society of Hypertension. <i>Cardiology and Therapy</i> , 2020 , 9, 19-34	2.8	9
289	Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography. <i>Scientific Reports</i> , 2020 , 10, 5255	4.9	3
288	Confounding Factors in Renal Denervation Trials: Revisiting Old and Identifying New Challenges in Trial Design of Device Therapies for Hypertension. <i>Hypertension</i> , 2020 , 76, 1410-1417	8.5	18
287	Assessment of Retinal Arteriolar Morphology by SLDF. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2020 , 27-41	0.1	
286	Tissue sodium content in hypertension and related organ damage. <i>Journal of Hypertension</i> , 2020 , 38, 2363-2368	1.9	2

285	The influence of aircraft noise exposure on the systemic and renal haemodynamics. <i>European Journal of Preventive Cardiology</i> , 2020 ,	3.9	1
284	Relationship Between Ubiquitin-Specific Peptidase 18 and Hypertension in Polish Adult Male Subjects: A Cross-Sectional Pilot Study. <i>Medical Science Monitor</i> , 2020 , 26, e921919	3.2	0
283	Medication adherence in hypertension. <i>Journal of Hypertension</i> , 2020 , 38, 579-587	1.9	21
282	Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 364-371	6.4	8
281	Renal denervation: where do we stand and what is the relevance to the nephrologist?. <i>Nephrology Dialysis Transplantation</i> , 2020 ,	4.3	7
280	Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids. <i>Theranostics</i> , 2020 , 10, 8665-8676	12.1	8
279	Retinal arterial remodeling in patients with pheochromocytoma or paraganglioma and its reversibility following surgical treatment. <i>Journal of Hypertension</i> , 2020 , 38, 1551-1558	1.9	2
278	Metabolische Wirkungen und kardiovaskuläre Sicherheit einer oralen Dreifachtherapie des Typ-2-Diabetes: das Beispiel Metformin, Empagliflozin und Linagliptin. <i>Diabetologie Und Stoffwechsel</i> , 2020 , 15, 317-326	0.7	
277	Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. <i>Journal of Hypertension</i> , 2020 , 38, 2050-2058	1.9	4
276	Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. <i>European Heart Journal</i> , 2020 , 41, 231-238	9.5	16
275	Effects of the nitric oxide synthase inhibitor roxatidine (VAS203) on renal function in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 900-907	3.8	9
274	Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 3006-3017	15.1	37
273	Tissue sodium content in patients with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2019 , 33, 485-489	3.2	11
272	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. <i>Circulation</i> , 2019 ,	16.7	58
271	Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPPLICITY Registry. <i>European Heart Journal</i> , 2019 , 40, 3474-3482	9.5	95
270	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. <i>European Heart Journal</i> , 2019 , 40, 2032-2043	9.5	23
269	How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. <i>Cardiovascular Diabetology</i> , 2019 , 18, 44	8.7	46
268	Patient preference for therapies in hypertension: a cross-sectional survey of German patients. <i>Clinical Research in Cardiology</i> , 2019 , 108, 1331-1342	6.1	17

267	Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. <i>Hypertension</i> , 2019 , HYPERTENSIONAHA11913081	8.5	12
266	Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 1095-1105	5	36
265	Effects of renal denervation on blood pressure in hypertensive patients with end-stage renal disease: a single centre experience. <i>Clinical and Experimental Nephrology</i> , 2019 , 23, 749-755	2.5	7
264	New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. <i>International Journal of Cardiology: Hypertension</i> , 2019 , 3, 100022	1.6	
263	Left Ventricular Structure in Patients With Mild-to-Moderate CKD-a Magnetic Resonance Imaging Study. <i>Kidney International Reports</i> , 2019 , 4, 267-274	4.1	4
262	Lumen narrowing and increased wall to lumen ratio of retinal microcirculation are valuable biomarkers of hypertension-mediated cardiac damage. <i>Blood Pressure</i> , 2019 , 1-10	1.7	3
261	Renal denervation improves 24-hour central and peripheral blood pressures, arterial stiffness, and peripheral resistance. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 366-372	2.3	11
260	Percutaneous Creation of a Central Iliac Arteriovenous Anastomosis for the Treatment of Arterial Hypertension. <i>Current Hypertension Reports</i> , 2018 , 20, 18	4.7	4
259	Retinal capillary and arteriolar changes in patients with chronic kidney disease. <i>Microvascular Research</i> , 2018 , 118, 121-127	3.7	13
258	Retinal vascular resistance in arterial hypertension. <i>Blood Pressure</i> , 2018 , 27, 82-87	1.7	7
257	Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV. <i>Journal of Hypertension</i> , 2018 , 36, 680-689	1.9	24
256	Impact of renal denervation on tissue Na content in treatment-resistant hypertension. <i>Clinical Research in Cardiology</i> , 2018 , 107, 42-48	6.1	11
255	A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. <i>American Heart Journal</i> , 2018 , 195, 115-129	4.9	39
254	Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 102-112	4.3	11
253	Assessment of Target Organ Damage 2018 , 189-199		
252	SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. <i>Cardiovascular Diabetology</i> , 2018 , 17, 5	8.7	97
251	Individualised treatment targets in patients with type-2 diabetes and hypertension. <i>Cardiovascular Diabetology</i> , 2018 , 17, 18	8.7	13
250	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018 , 39, 3021-3104	9.5	3698

249	Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>European Heart Journal</i> , 2018 , 39, 3105-3114	9.5	54
248	Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	7
247	Central arteriovenous anastomosis to treat resistant hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2018 , 27, 8-15	3.5	5
246	MASKed-unconTrolled hypERTension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. <i>BMJ Open</i> , 2018 , 8, e021038	10.38	20
245	Secretory Capacity of Pancreatic Beta-Cells Is Enhanced 6 Months After Renal Denervation in Hypertensive Patients. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 3372-3374	15.1	4
244	2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. <i>Journal of Hypertension</i> , 2018 , 36, 2197-2267	1.9	1262
243	Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease. <i>Hypertension</i> , 2018 , 72, 929-936	8.5	18
242	Early vascular parameters in the micro- and macrocirculation in type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2018 , 17, 128	8.7	13
241	European Society of Hypertension position paper on renal denervation 2018. <i>Journal of Hypertension</i> , 2018 , 36, 2042-2048	1.9	24
240	Application of a central iliac arteriovenous coupler device in severe treatment-resistant hypertension: a 3.5-year follow-up. <i>Journal of Hypertension</i> , 2018 , 36, 2471-2477	1.9	0
239	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet, The</i> , 2018 , 391, 2346-2355	40	358
238	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. <i>Lancet, The</i> , 2018 , 391, 2335-2345	40	301
237	Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 1867-1876	12.7	112
236	Low dose-eplerenone treatment decreases aortic stiffness in patients with resistant hypertension. <i>Journal of Clinical Hypertension</i> , 2017 , 19, 669-676	2.3	18
235	A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. <i>Cardiovascular Diabetology</i> , 2017 , 16, 26	8.7	89
234	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>Lancet, The</i> , 2017 , 389, 2226-2237	40	171
233	Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: A consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH). <i>European Heart Journal Cardiovascular Imaging</i> , 2017 , 18, 945-960	4.1	27
232	Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension: One-Year Results From the ROX CONTROL HTN Trial. <i>Hypertension</i> , 2017 , 70, 1099-1105	8.5	31

231	Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients. <i>Hypertension</i> , 2017 , 70, 938-948	8.5	19
230	Retinal capillary rarefaction in patients with untreated mild-moderate hypertension. <i>BMC Cardiovascular Disorders</i> , 2017 , 17, 300	2.3	28
229	Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017 , 136, 1167-1169	16.7	78
228	Accuracy of Cuff-Measured Blood Pressure: Systematic Reviews and Meta-Analyses. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 572-586	15.1	109
227	Hypertonie und Dyslipidämie. <i>Gastroenterologe</i> , 2017 , 12, 294-299	0.1	1
226	Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis. <i>Free Radical Research</i> , 2017 , 51, 14-23	4	5
225	Increased Aldosterone Release During Head-Up Tilt in Early Primary Hypertension. <i>American Journal of Hypertension</i> , 2017 , 30, 484-489	2.3	
224	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. <i>Lancet, The</i> , 2017 , 390, 2160-2170	40	406
223	Mid-Term Vascular Safety of Renal Denervation Assessed by Follow-up MR Imaging. <i>CardioVascular and Interventional Radiology</i> , 2016 , 39, 426-32	2.7	8
222	Scientific Data and Transparency of Conflict of Interest Are Important, Not Biased Editorial Without Facts. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 2263	5	6
221	Improvement in Retinal Capillary Rarefaction After Valsartan Treatment in Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 1112-1118	2.3	17
220	Diabetes und Hypertonie. <i>Diabetologe</i> , 2016 , 12, 312-318	0.2	
219	Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry. <i>BMC Cardiovascular Disorders</i> , 2016 , 16, 56	2.3	15
218	Externally Delivered Focused Ultrasound for Renal Denervation. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1292-1299	5	22
217	Adherence to Antihypertensive Medication in Treatment-Resistant Hypertension Undergoing Renal Denervation. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	43
216	Retinal Capillary Rarefaction in Patients with Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2016 , 11, e0162608	3.7	16
215	Alternative Methods for Renal Denervation. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2016 , 321-337	0.1	
214	Early Signs of End-Organ Damage in Retinal Arterioles in Patients with Type 2 Diabetes Compared to Hypertensive Patients. <i>Microcirculation</i> , 2016 , 23, 447-55	2.9	10

213	The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes: A Subanalysis of the ROADMAP Study. <i>Medicine (United States)</i> , 2016 , 95, e3122	1.8	5
212	Renal denervation reduces office and ambulatory heart rate in patients with uncontrolled hypertension: 12-month outcomes from the global SYMPLICITY registry. <i>Journal of Hypertension</i> , 2016 , 34, 2480-2486	1.9	17
211	Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	19
210	The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence. <i>Journal of Hypertension</i> , 2016 , 34, 2475-2479	1.9	7
209	Why in 2016 are patients with hypertension not 100% controlled? A call to action. <i>Journal of Hypertension</i> , 2016 , 34, 1480-8	1.9	31
208	Non-invasive Renal Denervation: Update on External Ultrasound Approaches. <i>Current Hypertension Reports</i> , 2016 , 18, 48	4.7	6
207	Reproducibility of Kidney Perfusion Measurements With Arterial Spin Labeling at 1.5 Tesla MRI Combined With Semiautomatic Segmentation for Differential Cortical and Medullary Assessment. <i>Medicine (United States)</i> , 2016 , 95, e3083	1.8	14
206	Renal denervation in hypertensive patients not on blood pressure lowering drugs. <i>Clinical Research in Cardiology</i> , 2016 , 105, 755-62	6.1	17
205	Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial. <i>Diabetologia</i> , 2016 , 59, 2579-2587	10.3	18
204	Cocoa Flavanol Cardiovascular Effects Beyond Blood Pressure Reduction. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 352-8	2.3	18
203	Two-Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Non-Interventional Prospective Study. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 647-54	2.3	2
202	Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 1045-1053	2.3	2
201	Circadian rhythm and day to day variability of serum potassium concentration: a pilot study. <i>Journal of Nephrology</i> , 2015 , 28, 165-72	4.8	10
200	Wilder® principle: pre-treatment value determines post-treatment response. <i>European Heart Journal</i> , 2015 , 36, 576-9	9.5	31
199	New approaches in the treatment of hypertension. <i>Circulation Research</i> , 2015 , 116, 1074-95	15.7	159
198	First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. <i>Hypertension</i> , 2015 , 65, 766-74	8.5	139
197	Damage of Retinal Arterioles in Hypertension 2015 , 127-142		
196	Renal Denervation for Resistant Hypertension: Past, Present, and Future. <i>Current Hypertension Reports</i> , 2015 , 17, 65	4.7	5

195	Retinal microperfusion after renal denervation in treatment-resistant hypertensive patients. <i>Clinical Research in Cardiology</i> , 2015 , 104, 782-9	6.1	4
194	Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension. <i>Clinical Research in Cardiology</i> , 2015 , 104, 672-8	6.1	35
193	Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin. <i>Clinical Research in Cardiology</i> , 2015 , 104, 621-31	6.1	13
192	Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. <i>Hypertension</i> , 2015 , 65, 193-9	8.5	84
191	The impact of age on the benefits and risks of aliskiren treatment: analyses of the 3A registry. <i>Journal of Human Hypertension</i> , 2015 , 29, 316-23	2.6	
190	Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 947-53	2.3	7
189	Effect of aliskiren on vascular remodelling in small retinal circulation. <i>Journal of Hypertension</i> , 2015 , 33, 2491-9	1.9	9
188	The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry. <i>Trials</i> , 2015 , 16, 581	2.8	4
187	Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. <i>Journal of Hypertension</i> , 2015 , 33, 1261-6	1.9	77
186	New developments in the pathogenesis of obesity-induced hypertension. <i>Journal of Hypertension</i> , 2015 , 33, 1499-508	1.9	56
185	Managing Treatment-Resistant Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015 , 22 Suppl 1, S11-3	2.9	1
184	Retinal Circulation in Arterial Disease 2015 , 397-414		2
183	Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry. <i>BMC Endocrine Disorders</i> , 2015 , 15, 23	3.3	7
182	Olmesartan improves pulse wave velocity and lowers central systolic blood pressure and ambulatory blood pressure in patients with metabolic syndrome. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 98-104	2.3	6
181	Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. <i>Lancet, The</i> , 2015 , 385, 1634-41	4.0	121
180	Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension. <i>EuroIntervention</i> , 2015 , 11, 110-6	3.1	32
179	Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2014 , 13, 19	8.7	51
178	A guide for easy- and difficult-to-treat hypertension. <i>International Journal of Cardiology</i> , 2014 , 172, 17-23.	2.2	17

177	Renal denervation--implications for chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2014 , 10, 305-13	14.9	21
176	Hypertension: How should data from SYMPLICITY HTN-3 be interpreted?. <i>Nature Reviews Cardiology</i> , 2014 , 11, 375-6	14.8	15
175	1-Year outcomes of hypertension management in 13,000 outpatients under practice conditions: prospective 3A registry. <i>International Journal of Cardiology</i> , 2014 , 176, 589-94	3.2	1
174	Diagnosis and treatment of resistant hypertension. <i>Blood Pressure</i> , 2014 , 23, 193-9	1.7	3
173	Invasive treatment of resistant hypertension: present and future. <i>Current Hypertension Reports</i> , 2014 , 16, 488	4.7	5
172	Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. <i>Diabetologia</i> , 2014 , 57, 2019-29	10.3	34
171	Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. <i>European Heart Journal</i> , 2014 , 35, 1752-9	9.5	186
170	Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide. <i>Clinical Drug Investigation</i> , 2014 , 34, 403-11	3.2	16
169	Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014 , 1842, 558-65	6.9	18
168	Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised Assessment Study in ACE intolerant subjects with cardiovascular Disease subanalysis. <i>Journal of Hypertension</i> , 2014 , 32, 1334-41	1.9	11
167	Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. <i>Journal of Hypertension</i> , 2014 , 32, 1888-97	1.9	55
166	Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes. <i>Journal of Hypertension</i> , 2014 , 32, 2267-76; discussion 2276	1.9	5
165	Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. <i>American Journal of Nephrology</i> , 2014 , 40, 572-81	4.6	27
164	Effects of folic acid on renal endothelial function in patients with diabetic nephropathy: results from a randomized trial. <i>Clinical Science</i> , 2014 , 127, 499-505	6.5	14
163	Urinary albumin excretion from spot urine samples predict all-cause and stroke mortality in Africans. <i>American Journal of Hypertension</i> , 2014 , 27, 811-8	2.3	9
162	2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. <i>Blood Pressure</i> , 2014 , 23, 3-16	1.7	474
161	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. <i>Journal of Hypertension</i> , 2014 , 32, 1741-50	1.9	31
160	First experience in analysing pulsatile retinal capillary flow and arteriolar structural parameters measured noninvasively in hypertensive patients. <i>Journal of Hypertension</i> , 2014 , 32, 2246-52; discussion 2252	1.9	11

159	Disproportional decrease in office blood pressure compared with 24-hour ambulatory blood pressure with antihypertensive treatment: dependency on pretreatment blood pressure levels. <i>Hypertension</i> , 2014 , 64, 1067-72	8.5	31
158	Improvement of albuminuria after renal denervation. <i>International Journal of Cardiology</i> , 2014 , 173, 311-52	5.2	59
157	What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. <i>EuroIntervention</i> , 2014 , 9, 1027-35	3.1	38
156	EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy--rationale and design of the EARLY hypertension registry. <i>BMC Cardiovascular Disorders</i> , 2013 , 13, 46	2.3	6
155	Does renal artery supply indicate treatment success of renal denervation?. <i>CardioVascular and Interventional Radiology</i> , 2013 , 36, 987-91	2.7	7
154	25-hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment. <i>Clinical Research in Cardiology</i> , 2013 , 102, 299-304	6.1	14
153	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). <i>Hipertension Y Riesgo Vascular</i> , 2013 , 30, 4-91	0.5	7
152	International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 2031-45	15.1	104
151	Renal denervation in moderate treatment-resistant hypertension. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1880-6	15.1	73
150	Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. <i>Hypertension</i> , 2013 , 61, e17	8.5	7
149	23Na magnetic resonance imaging-determined tissue sodium in healthy subjects and hypertensive patients. <i>Hypertension</i> , 2013 , 61, 635-40	8.5	243
148	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). <i>Revista Espanola De Cardiologia</i> , 2013 , 66, 880.e1-880.e64	1.5	13
147	Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 129-35	3.8	24
146	Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. <i>International Journal of Cardiology</i> , 2013 , 168, 2214-20	3.2	101
145	2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. <i>Blood Pressure</i> , 2013 , 22, 193-278	18.7	286
144	Central pulse pressure is an independent determinant of vascular remodeling in the retinal circulation. <i>Hypertension</i> , 2013 , 61, 1340-5	8.5	55
143	Poor glycemic control is related to increased nitric oxide activity within the renal circulation of patients with type 2 diabetes. <i>Diabetes Care</i> , 2013 , 36, 4071-5	14.6	11
142	2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>Journal of Hypertension</i> , 2013 , 31, 1281-357	1.9	3363

141	Optimizing blood pressure control in hypertension: the need to use ABPM. <i>Blood Pressure</i> , 2013 , 22, 65-72	1.7	7
140	Vascular and renal hemodynamic changes after renal denervation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013 , 8, 1195-201	6.9	41
139	Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. <i>Circulation</i> , 2013 , 128, 132-40	16.7	199
138	2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2013 , 31, 1925-38	1.9	635
137	Local application of tropicamide 0.5% reduces retinal capillary blood flow. <i>Blood Pressure</i> , 2013 , 22, 371-6	6.7	21
136	Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring. <i>Journal of Human Hypertension</i> , 2013 , 27, 715-20	2.6	17
135	Review of direct renin inhibition by aliskiren. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2013 , 14, 193-6	3	17
134	Haemoglobin and vascular function in the human retinal vascular bed. <i>Journal of Hypertension</i> , 2013 , 31, 775-81	1.9	3
133	Clinical situations associated with difficult-to-control hypertension. <i>Journal of Hypertension</i> , 2013 , 31 Suppl 1, S3-8	1.9	15
132	Catheter-based Renal Sympathetic Denervation - Long-term SymplcityRenal Denervation Clinical Evidence, New Data and Future Perspectives. <i>Interventional Cardiology Review</i> , 2013 , 8, 118-123	4.2	5
131	Rationale and design of a large registry on renal denervation: the Global SYMPLICITY registry. <i>EuroIntervention</i> , 2013 , 9, 484-92	3.1	42
130	Updated ESH position paper on interventional therapy of resistant hypertension. <i>EuroIntervention</i> , 2013 , 9 Suppl R, R58-66	3.1	54
129	Ruling out secondary causes of hypertension. <i>EuroIntervention</i> , 2013 , 9 Suppl R, R21-8	3.1	5
128	(23)Na magnetic resonance imaging of tissue sodium. <i>Hypertension</i> , 2012 , 59, 167-72	8.5	161
127	Current status of renal denervation in resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2012 , 6, 414-6		2
126	Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplcity HTN-2 randomized, controlled trial. <i>Circulation</i> , 2012 , 126, 2976-82	16.7	343
125	Salt and hypertension: is salt dietary reduction worth the effort?. <i>American Journal of Medicine</i> , 2012 , 125, 433-9	2.4	118
124	Influence of blood flow on arteriolar wall-to-lumen ratio in the human retinal circulation in vivo. <i>Microvascular Research</i> , 2012 , 83, 111-7	3.7	18

123	Rosuvastatin improves pulse wave reflection by restoring endothelial function. <i>Microvascular Research</i> , 2012 , 84, 60-4	3.7	14
122	Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice - study rationale and protocol of DIALOGUE. <i>Cardiovascular Diabetology</i> , 2012 , 11, 148	8.7	1
121	Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: a direction for future research. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 799-801	2.3	30
120	Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. <i>Hypertension</i> , 2012 , 60, 419-24	8.5	245
119	Barriers to cardiovascular risk prevention and management in Germany--an analysis of the EURIKA study. <i>Vascular Health and Risk Management</i> , 2012 , 8, 177-86	4.4	10
118	Tonic postganglionic sympathetic inhibition induced by afferent renal nerves?. <i>Hypertension</i> , 2012 , 59, 467-76	8.5	31
117	Impaired increase of retinal capillary blood flow to flicker light exposure in arterial hypertension. <i>Hypertension</i> , 2012 , 60, 871-6	8.5	20
116	Reversibility of the effects of aliskiren in the renal versus systemic circulation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012 , 7, 258-64	6.9	11
115	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. <i>Journal of Hypertension</i> , 2012 , 30, 1047-55	7.8	95
114	Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group Hypertension Arrhythmias and Thrombosis of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2012 , 30, 239-52	1.9	138
113	Comment on ESH position paper. <i>Journal of Hypertension</i> , 2012 , 30, 2443	1.9	3
112	ESH position paper: renal denervation - an interventional therapy of resistant hypertension. <i>Journal of Hypertension</i> , 2012 , 30, 837-41	1.9	187
111	The Optic Fundus and Retinal Circulation: New Technology for an Old Examination 2012 , 157-168		
110	Validation of a therapeutic scheme for the treatment of resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2011 , 5, 498-504		13
109	New software analyses increase the reliability of measurements of retinal arterioles morphology by scanning laser Doppler flowmetry in humans. <i>Journal of Hypertension</i> , 2011 , 29, 777-82	1.9	53
108	Basal nitric oxide activity is an independent determinant of arteriolar structure in the human retinal circulation. <i>Journal of Hypertension</i> , 2011 , 29, 123-9	1.9	13
107	Physician attitudes to blood pressure control: findings from the Supporting Hypertension Awareness and Research Europe-wide survey. <i>Journal of Hypertension</i> , 2011 , 29, 1633-40	1.9	32
106	Cerebral microangiopathy in treatment-resistant hypertension. <i>Journal of Clinical Hypertension</i> , 2011 , 13, 582-7	2.3	7

105	Changes in albuminuria predict mortality and morbidity in patients with vascular disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2011 , 22, 1353-64	12.7	190
104	Reduction in basal nitric oxide activity causes albuminuria. <i>Diabetes</i> , 2011 , 60, 572-6	0.9	22
103	Urinary sodium and potassium excretion and risk of cardiovascular events. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 2229-38	27.4	375
102	Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). <i>Circulation</i> , 2011 , 124, 1727-36	16.7	121
101	Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. <i>Journal of Human Hypertension</i> , 2011 , 25, 354-63	2.6	14
100	Remodeling of retinal small arteries in hypertension. <i>American Journal of Hypertension</i> , 2011 , 24, 1267-73	3.3	45
99	Beyond salt: lifestyle modifications and blood pressure. <i>European Heart Journal</i> , 2011 , 32, 3081-7	9.5	85
98	Telmisartan in incipient and overt diabetic renal disease. <i>Journal of Nephrology</i> , 2011 , 24, 263-73	4.8	8
97	Renal protection with angiotensin receptor blockers: where do we stand. <i>Journal of Nephrology</i> , 2011 , 24, 569-80	4.8	14
96	Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice. <i>Vascular Health and Risk Management</i> , 2010 , 6, 803-11	4.4	12
95	Improvement of hypertension management by structured physician education and feedback system: cluster randomized trial. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010 , 17, 271-9		35
94	Change in augmentation index during NOS inhibition, an index of basal NO production, is an independent determinant of large-artery function. <i>Kidney and Blood Pressure Research</i> , 2010 , 33, 343-51	3.1	5
93	End organ damage in hypertension. <i>Deutsches Arzteblatt International</i> , 2010 , 107, 866-73	2.5	73
92	Angiotensin II-type 2 receptor: emerging target for cardiovascular protection. <i>American Journal of Hypertension</i> , 2010 , 23, 220	2.3	1
91	Measurement of kidney perfusion by magnetic resonance imaging: comparison of MRI with arterial spin labeling to para-aminohippuric acid plasma clearance in male subjects with metabolic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 1126-33	4.3	62
90	Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 2299-307	15.1	306
89	Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. <i>Lancet, The</i> , 2010 , 376, 1903-9	4.0	1577
88	Renal resistive index in addition to low-grade albuminuria complements screening for target organ damage in therapy-resistant hypertension. <i>Journal of Hypertension</i> , 2010 , 28, 608-14	1.9	36

87	Relation of the first hypertension-associated event with medication, compliance and persistence in naïve hypertensive patients after initiating monotherapy. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2010 , 48, 173-83	2	13
86	Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. <i>Circulation</i> , 2009 , 119, 417-25	16.7	116
85	Wall-to-lumen ratio of retinal arterioles and arteriole-to-venule ratio of retinal vessels in patients with cerebrovascular damage 2009 , 50, 4351-9		54
84	Wall-to-lumen ratio of retinal arterioles as a tool to assess vascular changes. <i>Hypertension</i> , 2009 , 54, 384-7	5	50
83	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Journal of Hypertension</i> , 2009 , 27, 2121-58	1.9	1004
82	Hypertension and Diabetes: what are the pros to treating early surrogates?. <i>Diabetes Care</i> , 2009 , 32 Suppl 2, S294-7	14.6	
81	Angiotensin blockade to reduce microvascular damage in diabetes mellitus. <i>Deutsches Arzteblatt International</i> , 2009 , 106, 556-62	2.5	6
80	Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus. <i>American Journal of Kidney Diseases</i> , 2009 , 53, 281-9	7.4	30
79	The role of statins in the treatment of the metabolic syndrome. <i>Current Hypertension Reports</i> , 2009 , 11, 143-9	4.7	13
78	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Blood Pressure</i> , 2009 , 18, 308-47	1.7	186
77	Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. <i>Journal of Hypertension</i> , 2009 , 27, 673-9	1.9	45
76	Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. <i>Journal of Hypertension</i> , 2009 , 27, 1493-501	1.9	34
75	Wall-to-lumen ratio of retinal arterioles is related with urinary albumin excretion and altered vascular reactivity to infusion of the nitric oxide synthase inhibitor N-monomethyl-L-arginine. <i>Journal of Hypertension</i> , 2009 , 27, 2201-8	1.9	35
74	Effect of telmisartan on renal outcomes: a randomized trial. <i>Annals of Internal Medicine</i> , 2009 , 151, 1-10, W1-2	8	116
73	Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice. <i>Vascular Health and Risk Management</i> , 2009 , 5, 991-1000	4.4	3
72	Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia. <i>Journal of Nephrology</i> , 2009 , 22, 675-81	4.8	7
71	Blood pressure control in patients with comorbidities. <i>Journal of Clinical Hypertension</i> , 2008 , 10, 624-31	2.3	24
70	Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. <i>Atherosclerosis</i> , 2008 , 196, 704-11	3.1	27

69	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. <i>Lancet, The</i> , 2008 , 372, 547-53	4.0	1179
68	Left ventricular hypertrophy and clinical outcomes in hypertensive patients. <i>American Journal of Hypertension</i> , 2008 , 21, 500-8	2.3	174
67	Effects of angiotensin II type 1-receptor blockade on retinal endothelial function. <i>Journal of Hypertension</i> , 2008 , 26, 516-22	1.9	10
66	Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. <i>Journal of Hypertension</i> , 2008 , 26, 403-11	1.9	151
65	The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. <i>Journal of Hypertension</i> , 2008 , 26, 1487-96	1.9	159
64	Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans. <i>Journal of Hypertension</i> , 2008 , 26, 110-6	1.9	21
63	Analysis of retinal arteriolar structure in never-treated patients with essential hypertension. <i>Journal of Hypertension</i> , 2008 , 26, 1427-34	1.9	71
62	Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2008 , 23, 1346-54	4.3	38
61	Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. <i>International Journal of Clinical Practice</i> , 2007 , 61, 1461-8	2.9	70
60	Low-grade albuminuria and cardiovascular risk : what is the evidence?. <i>Clinical Research in Cardiology</i> , 2007 , 96, 247-57	6.1	84
59	2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>Journal of Hypertension</i> , 2007 , 25, 1105-87	1.9	3825
58	Increased wall:lumen ratio of retinal arterioles in male patients with a history of a cerebrovascular event. <i>Hypertension</i> , 2007 , 50, 623-9	8.5	113
57	Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. <i>Diabetes Care</i> , 2007 , 30, 1351-6	14.6	101
56	2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2007 , 25, 1751-62	1.9	871
55	The potential role of prorenin in diabetic nephropathy. <i>Journal of Hypertension</i> , 2007 , 25, 1323-6	1.9	6
54	High sodium intake modulates left ventricular mass in patients with G expression of +1675 G/A angiotensin II receptor type 2 gene. <i>Journal of Hypertension</i> , 2007 , 25, 1627-32	1.9	13
53	Renin-angiotensin system and cardiovascular risk. <i>Lancet, The</i> , 2007 , 369, 1208-19	4.0	507
52	Impaired basal NO activity in patients with glomerular disease and the influence of oxidative stress. <i>Kidney International</i> , 2006 , 70, 1177-81	9.9	22

51	Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. <i>Circulation</i> , 2005 , 111, 1012-8	16.7	438
50	Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. <i>American Heart Journal</i> , 2005 , 149, 473	4.9	110
49	Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16, 3038-45	12.7	121
48	The role of nitric oxide in the regulation of glomerular haemodynamics in humans. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 1392-7	4.3	39
47	Impaired endothelial function of the retinal vasculature in hypertensive patients. <i>Stroke</i> , 2004 , 35, 1289-93	4.3	126
46	Increased response of renal perfusion to the antioxidant vitamin C in type 2 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 2513-8	4.3	32
45	P-204: Aliskiren, a novel orally effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an at1-receptor blocker in hypertensive patients. <i>American Journal of Hypertension</i> , 2004 , 17, S108	2.3	4
44	Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. <i>American Journal of Hypertension</i> , 2003 , 16, 1030-5	2.3	28
43	A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. <i>American Journal of Medicine</i> , 2003 , 115, 41-6	2.4	574
42	Rapid nongenomic effects of aldosterone on human forearm vasculature. <i>Hypertension</i> , 2003 , 42, 156-60	3.5	107
41	L-arginine-induced vasodilation of the renal vasculature is not altered in hypertensive patients with type 2 diabetes. <i>Diabetes Care</i> , 2003 , 26, 1836-40	14.6	15
40	Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. <i>Kidney International</i> , 2002 , 61, 1462-8	9.9	36
39	Impact of NO-synthase inhibition on renal hemodynamics in normotensive and hypertensive subjects. <i>Journal of Hypertension</i> , 2002 , 20, 525-30	1.9	18
38	Assessment of endothelial function of the renal vasculature in human subjects. <i>American Journal of Hypertension</i> , 2002 , 15, 3-9	2.3	69
37	Impaired sodium excretion during mental stress in mild essential hypertension. <i>Hypertension</i> , 2001 , 37, 923-7	8.5	22
36	Pharmacokinetics of Valsartan in Hypertensive Patients on Long-Term Haemodialysis. <i>Clinical Drug Investigation</i> , 2001 , 21, 59-66	3.2	5
35	Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 175-82	15.1	76
34	Plasma soluble adhesion molecules and endothelium-dependent vasodilation in early human atherosclerosis. <i>Clinical Science</i> , 2000 , 98, 521-529	6.5	19

33	Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. <i>Clinical Science</i> , 2000 , 99, 293-302	6.5	28
32	Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. <i>Clinical Science</i> , 2000 , 99, 293	6.5	9
31	Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. <i>Journal of Hypertension</i> , 2000 , 18, 363-74	1.9	119
30	Hypertension and the heart. <i>Journal of Human Hypertension</i> , 2000 , 14, 597-604	2.6	63
29	Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. <i>Clinical Science</i> , 2000 , 99, 293-302	6.5	3
28	Diuretic therapy and the risk for renal cell carcinoma. <i>Journal of Nephrology</i> , 2000 , 13, 343-6	4.8	7
27	Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. <i>American Journal of Hypertension</i> , 1999 , 12, 418-422	2.3	
26	Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. <i>American Journal of Hypertension</i> , 1999 , 12, 418-422	2.3	22
25	Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. <i>American Journal of Hypertension</i> , 1998 , 11, 1394-404	2.3	48
24	Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. <i>Circulation</i> , 1998 , 98, 211-6	16.7	211
23	Impact of dietary sodium intake on left ventricular diastolic filling in early essential hypertension. <i>European Heart Journal</i> , 1998 , 19, 951-8	9.5	27
22	Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). <i>Nephrology Dialysis Transplantation</i> , 1998 , 13, 564-9	4.3	140
21	Renal and systemic hemodynamics in black and white hypertensive patients. <i>American Journal of Hypertension</i> , 1997 , 10, 971-8	2.3	4
20	Glomerular hyperfiltration during sympathetic nervous system activation in early essential hypertension. <i>Journal of the American Society of Nephrology: JASN</i> , 1997 , 8, 893-900	12.7	63
19	Salt. A perpetrator of hypertensive target organ disease?. <i>Archives of Internal Medicine</i> , 1997 , 157, 2449-52		38
18	Preeclampsia -- a state of sympathetic overactivity. <i>New England Journal of Medicine</i> , 1996 , 335, 1480-5	59.2	468
17	Effects of angiotensin converting enzyme inhibitor on renal haemodynamics during mental stress. <i>Journal of Hypertension</i> , 1996 , 14, 1201-7	1.9	9
16	Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. <i>Circulation</i> , 1996 , 94, 1304-9	16.7	92

15	Accelerated decline in renal perfusion with aging in essential hypertension. <i>Hypertension</i> , 1994 , 23, 351-8.5	50
14	Salt intake, blood pressure, and cardiovascular structure. <i>Cardiovascular Drugs and Therapy</i> , 1994 , 8, 425-33	14
13	Renal hemodynamic response to stress is influenced by ACE-inhibitors. <i>Clinical Nephrology</i> , 1994 , 42, 381-8	2.1 10
12	Nephroprotection by antihypertensive agents. <i>Journal of Cardiovascular Pharmacology</i> , 1994 , 24 Suppl 2, S55-64	3.1
11	Does obesity influence early target organ damage in hypertensive patients?. <i>Circulation</i> , 1993 , 87, 1482-86.7	56
10	Obesity as a determinant for response to antihypertensive treatment. <i>BMJ: British Medical Journal</i> , 1993 , 307, 537-40	37
9	Obese hypertensive patients are less effectively treated than lean hypertensives. <i>Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension</i> , 1993 , 11, S348-9	
8	Risks versus benefits of withdrawing antihypertensive therapy. <i>Drug Safety</i> , 1992 , 7, 395-403	5.1 4
7	Stress response pattern in obesity and systemic hypertension. <i>American Journal of Cardiology</i> , 1992 , 70, 1035-9	3 22
6	Hypertensive heart disease--significance of left ventricular hypertrophy. <i>Journal of Cardiovascular Pharmacology</i> , 1992 , 20 Suppl 6, S50-5	3.1 4
5	Antihypertensive therapy. To stop or not to stop?. <i>JAMA - Journal of the American Medical Association</i> , 1991 , 265, 1566-71	27.4 17
4	When is discontinuation of antihypertensive therapy indicated?. <i>Cardiovascular Drugs and Therapy</i> , 1990 , 4, 1487-94	3.9 3
3	Reversal of left ventricular hypertrophy: a desirable therapeutic goal?. <i>Journal of Cardiovascular Pharmacology</i> , 1990 , 16 Suppl 6, S16-22	3.1 1
2	Cardiac performance after reduction of myocardial hypertrophy. <i>American Journal of Medicine</i> , 1989 , 87, 22-7	2.4 58
1	Dietary salt intake. A determinant of cardiac involvement in essential hypertension. <i>Circulation</i> , 1988 , 78, 951-6	16.7 239